BIO 300

Drug Profile

BIO 300

Alternative Names: BIO-300

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA)
  • Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation
  • Class Radioprotectives
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Haematopoietic cell growth factor stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome

Most Recent Events

  • 12 Oct 2017 BIO 300 is still in phase-I/II development for Radiation injuries (Prevention) (in patients with non-small cell lung cancer) in USA (PO) (NCT02567799)
  • 10 Oct 2017 Humanetics receives a Humanetics receives a grant from the National Aeronautics and Space Administration for evaluation of BIO 300 in prevention of radiation induced damage to the cardiac tissue
  • 12 Sep 2017 BIO 300 is still in phase I development for Acute radiation syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top